Friday, May 30, 2008
Hilton Chicago
Grand Ballroom, 2nd Floor
Chicago, Illinois
This independent satellite symposium will discuss the pathogenesis and progression of lymphoproliferative disease. Data will also be presented from key clinical trials evaluating current and investigational therapeutic options.
This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.
Purpose
The purpose of this activity is to enhance the quality of care provided by healthcare professionals treating patients with lymphoproliferative disease by sharing up-to-date evidence-based information on optimal patient management strategies.
Target Audience
This activity is intended for physicians, registered nurses, and other healthcare professionals who treat patients with lymphoproliferative disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Identify key signaling pathways and transcription factors that are disrupted in lymphoproliferative diseases
-
Describe the advantages and disadvantages of using cytotoxic agents for treating patients with lymphoproliferative diseases
-
Discuss recent clinical trial data on the use of monoclonal antibodies in induction and maintenance therapy in lymphoproliferative diseases
-
Cite key classes of targeted agents and clinical data supporting their use for the treatment of lymphoproliferative diseases